mannitol has been researched along with rifampin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (46.67) | 29.6817 |
| 2010's | 6 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| de Jonge, AJ; Klapwijk, PM; Rörsch, A; Schilperoort, RA | 1 |
| Bennett, JE | 1 |
| Barroso, EC; Bushen, OY; Façanha, MC; Guerrant, RL; Lima, AA; Monteiro, HS; Peloquin, CA; Pinheiro, VG; Ramos, LM | 1 |
| Chan, HK; Changsan, N; Separovic, F; Srichana, T | 1 |
| Mizoe, T; Okada, H; Ozeki, T | 1 |
| Kabasawa, T; Ohashi, K; Okada, H; Ozeki, T | 1 |
| Changsan, N; Nilkaeo, A; Pungrassami, P; Srichana, T | 1 |
| Ho, SC; Hsiong, CH; Hu, OY; Huang, TY; Shih, TY | 1 |
| Elgindy, NA; Mehanna, MM; Mohyeldin, SM | 1 |
2 review(s) available for mannitol and rifampin
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Chemotherapy of systemic mycoses (first of two parts).
Topics: Amphotericin B; Animals; Bicarbonates; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Infusions, Parenteral; Injections, Intra-Articular; Injections, Intravenous; Injections, Spinal; Kidney; Mannitol; Meningitis; Mycoses; Rifampin | 1974 |
1 trial(s) available for mannitol and rifampin
| Article | Year |
|---|---|
Selected pharmaceutical excipient prevent isoniazid and rifampicin induced hepatotoxicity.
Topics: Adult; Animals; Antitubercular Agents; Chemical and Drug Induced Liver Injury; Cytochrome P-450 CYP2E1 Inhibitors; Drug Combinations; Excipients; Female; Humans; Isoniazid; Male; Mannitol; Mice; Mice, Inbred Strains; Microsomes, Liver; Middle Aged; Mycobacterium tuberculosis; Rats; Rats, Sprague-Dawley; Rifampin; Young Adult | 2013 |
12 other study(ies) available for mannitol and rifampin
| Article | Year |
|---|---|
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
An enrichment technique for auxotrophs of Agrobacterium tumefaciens using a combination of carbenicillin and lysozyme.
Topics: Arginine; Bacteriological Techniques; Carbenicillin; Cycloserine; Fermentation; Galactose; Histidine; Leucine; Mannitol; Methylnitronitrosoguanidine; Muramidase; Mutagens; Mutation; Penicillin Resistance; Rhizobium; Rifampin | 1975 |
Intestinal permeability and malabsorption of rifampin and isoniazid in active pulmonary tuberculosis.
Topics: Adolescent; Adult; Aged; Antitubercular Agents; Case-Control Studies; Chromatography, High Pressure Liquid; Cross-Sectional Studies; Female; Humans; Intestinal Absorption; Isoniazid; Lactulose; Male; Mannitol; Middle Aged; Permeability; Rifampin; Tuberculosis, Pulmonary | 2006 |
Physicochemical characterization and stability of rifampicin liposome dry powder formulations for inhalation.
Topics: Administration, Inhalation; Aerosols; Anti-Bacterial Agents; Chemistry, Pharmaceutical; Cholesterol; Cryoprotective Agents; Drug Compounding; Drug Stability; Freeze Drying; Liposomes; Mannitol; Particle Size; Phosphatidylcholines; Powders; Rifampin; Technology, Pharmaceutical; Temperature; Time Factors | 2009 |
Application of a four-fluid nozzle spray drier to prepare inhalable rifampicin-containing mannitol microparticles.
Topics: Administration, Inhalation; Aerosols; Animals; Chemistry, Pharmaceutical; Desiccation; Drug Delivery Systems; Lung; Male; Mannitol; Particle Size; Rats; Rats, Sprague-Dawley; Rifampin | 2008 |
One-step preparation of rifampicin/poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis.
Topics: Administration, Inhalation; Administration, Intranasal; Aerosols; Animals; Antibiotics, Antitubercular; Cell Line; Drug Carriers; Drug Compounding; Lactic Acid; Lung; Macrophages, Alveolar; Male; Mannitol; Microscopy, Electron, Scanning; Microspheres; Nanoparticles; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Rats; Rats, Sprague-Dawley; Rifampin; Surface Properties | 2009 |
Monitoring safety of liposomes containing rifampicin on respiratory cell lines and in vitro efficacy against Mycobacterium bovis in alveolar macrophages.
Topics: Animals; Antibiotics, Antitubercular; Cell Line; Cryoprotective Agents; Drug Delivery Systems; Epithelial Cells; Freeze Drying; Humans; Liposomes; Macrophages, Alveolar; Mannitol; Microbial Sensitivity Tests; Mycobacterium bovis; Particle Size; Powders; Rats; Rifampin | 2009 |
Rifampicin-Carbohydrate Spray-Dried Nanocomposite: A Futuristic Multiparticulate Platform For Pulmonary Delivery.
Topics: A549 Cells; Administration, Inhalation; Aerosols; Calorimetry, Differential Scanning; Carbohydrates; Cell Death; Cell Survival; Drug Delivery Systems; Dry Powder Inhalers; Excipients; Humans; Lung; Mannitol; Nanocomposites; Particle Size; Rheology; Rifampin; Spectroscopy, Fourier Transform Infrared; Static Electricity; X-Ray Diffraction | 2019 |